Interesting- just as in the Hip study- the higher dose was not as effective as the lower and mid doses- overabundance of the PLX I think was the rationale in lower efficacy at higher doses?:
"All doses of PLX-R18 improved outcome of irradiated NHPs relative to placebo (dose of 4, 10 and 20M cells/kg increased survival by 33.3, 35.7 and 16.7% respectively). "
Also-
"Taken together, all doses of PLX-R18 positively affected survival rates and multiple hematological parameters of HS-ARS in rhesus monkeys and had no negative effects in either irradiated or non-irradiated monkeys."
Like we have heard before, when humans can report the side effects they encounter (Nausea?, Headache?- all hopefully minor) then we will see the full impact of full scale production.
News 
Market Data 
Discover 
AI
